



The National Institute for Innovation in Manufacturing Biopharmaceuticals

---

## AMERICAN INNOVATION AT WORK

---

### AN INDUSTRIAL REVOLUTION

---

NIIMBL (The National Institute for Innovation in Manufacturing Biopharmaceuticals) leverages a \$70 million investment from the National Institute of Standards and Technology (NIST), and is designed to innovate biomanufacturing in the United States. Through partnerships among industry, academia, non-profit organizations, and federal scientists, NIIMBL will accelerate biopharmaceutical manufacturing innovation, support the development of standards that enable more efficient and rapid manufacturing capabilities, and educate and train a world-leading biopharmaceutical manufacturing workforce, fundamentally advancing U.S. competitiveness in this industry.

### FOSTERING INNOVATION

---


Through the cooperation and collaboration of its members, NIIMBL promises to address long standing and upcoming industry challenges in the U.S. biopharmaceutical manufacturing landscape. NIIMBL will leverage federal, state, and local resources to advance the development and manufacturing of existing and emerging products including monoclonal antibodies, antibody-drug conjugates, cell immunotherapies, gene therapies, vaccines, and blood products. NIIMBL will address technology challenges as well as workforce development needs. Furthermore, NIIMBL will work to help establish relevant reference standards and materials, facilitate technology platforms to speed approval while maintaining safety and efficacy, and encouraging domestic investment in infrastructure.

### NIIMBL

- A Manufacturing USA institute designed to revolutionize biopharmaceutical manufacturing
- Solves industry challenges through partnership with industry, government, academia, and non-profits
- Partners with stakeholders to train and retrain a robust, 21st century workforce

### BENEFITS

- Shared risk of technology R&D and adoption through a broad investment ecosystem
- Accelerated process development
- Establishment of best practices
- Lower barrier for new technology introduction
- Sustainable processes and process development
- Access to better trained workforce
- Standardization of equipment, assays, parts, and methods
- Regulatory advancement
- Reduced cost of goods
- Supply-chain engagement, bridging gaps from researcher to supplier to manufacturer to end-user



## NATIONAL IMPACT

As a member of the Manufacturing USA network, NIIMBL will address biopharmaceutical manufacturing challenges and opportunities through the following:

1. Developing and de-risking transformative technologies/processes and facilitating their commercialization and implementation in the U.S.
2. Expanding the U.S. biomanufacturing sector through strategic collaborations that support the success of small-to-medium enterprises (SMEs) and that retain and attract biomanufacturers and suppliers of all sizes
3. Supporting best-in-class workforce training and educational capabilities to build the advanced, highly-skilled U.S. workforce required to support the future of the industry and to support the economy with high-wage, high-value jobs
4. Providing solutions to industry-wide technology limitations that will give the US both economic and security advantages through increased quality, speed to market, and lower costs
5. Sharing best practices and developing standards that bolster innovation, streamline regulatory approval, and promote regulatory harmonization
6. Catalyzing innovative regulatory approaches that enhance the accessibility, safety, potency, and efficacy of products

## MEMBERSHIP INFORMATION

Leverage the collective capabilities of NIIMBL by joining the consortium!

Please visit [NIIMBL.org](https://NIIMBL.org) to learn more.